Medical Necessity Letter for IVIG: What It Should Include and Why It Matters

A medical necessity letter can be the single document that determines whether an insurance company approves or denies IVIG therapy. Written by the prescribing physician, this letter explains in clinical detail why a specific patient needs intravenous immunoglobulin and why no alternative treatment is adequate. Understanding what makes a compelling letter, and what the insurer is actually looking for, helps patients advocate for stronger documentation from day one.

What Is a Medical Necessity Letter?

A letter of medical necessity is a formal document from a treating physician to an insurance company. It serves one purpose: to convince the insurer’s clinical reviewer that IVIG is not optional, not experimental, and not interchangeable with a cheaper alternative for this particular patient.

Insurance companies receive thousands of prior authorization requests for IVIG every year. The reviewers evaluating these requests are checking clinical criteria from the plan’s medical policy. A strong medical necessity letter does more than describe the diagnosis. It systematically addresses each criterion the insurer uses to make its coverage decision.

Patients do not write this letter themselves, but patients absolutely can influence its content. Knowing what should be in it allows you to have a focused conversation with your doctor and ensure nothing critical is left out.

When Is a Medical Necessity Letter Needed?

A medical necessity letter may be required or strongly recommended in several situations:

• Initial prior authorization: When IVIG is prescribed for the first time and the insurer requires clinical justification
• Prior authorization denial: When the insurer denies the initial request and the physician must provide additional evidence on appeal
• Off-label use: When IVIG is prescribed for a condition not listed in the drug’s FDA-approved indications, such as certain autoimmune conditions supported by clinical evidence but not yet formally approved
• Step therapy exception: When the physician needs to explain why the patient should skip the insurer’s preferred medication sequence
• Dose or frequency changes: When the prescribed IVIG dose exceeds what the insurer considers standard
• Reauthorization: When ongoing IVIG therapy needs renewal, especially if the insurer questions continued treatment

What a Strong Medical Necessity Letter Should Include

Every medical necessity letter for IVIG should contain the following sections. When you discuss the letter with your doctor, use this as a checklist to ensure completeness.

Patient Identification and Diagnosis

The letter should open with the patient’s identifying information, the specific diagnosis with ICD-10 code, and the date of diagnosis. For conditions like CIDP (chronic inflammatory demyelinating polyneuropathy), it should specify the diagnostic criteria that were met, such as the European Federation of Neurological Societies/Peripheral Nerve Society criteria.

Clinical History and Disease Course

This section tells the patient’s story in clinical terms. When did symptoms begin? How has the disease progressed? What functional limitations exist? The physician should describe the trajectory of the illness, not just a snapshot. An insurer reviewing this section needs to understand that this is a real person whose condition has been carefully evaluated over time.

Objective Clinical Findings

This is where laboratory data, diagnostic test results, and measurable clinical findings belong. For IVIG requests, this might include:

• Immunoglobulin levels (IgG, IgA, IgM) and specific antibody titers
• Nerve conduction study and electromyography (EMG) results
• Muscle strength testing scores
• Functional assessments such as the Overall Neuropathy Limitations Scale (ONLS) or Inflammatory Neuropathy Cause and Treatment (INCAT) disability score
• Relevant imaging or biopsy results

Numbers matter more than narratives to insurance reviewers. Specific quantitative findings, like “grip strength decreased from 45 kg to 22 kg over six months,” carry more weight than “patient reports worsening weakness.”

Previous Treatment History

The letter must document every relevant treatment that has been tried, including the medication name, dose, duration, and the specific reason it was discontinued. Did the patient experience adverse effects? Was the response inadequate? Were there contraindications to alternative therapies?

This section directly addresses step therapy requirements. If the insurer wants to know why the patient cannot take corticosteroids or other immunosuppressants first, the treatment history should provide a clear, documented answer.

Evidence Supporting IVIG

The physician should cite peer-reviewed medical literature, clinical guidelines, and established treatment protocols supporting IVIG for the patient’s specific diagnosis. References from organizations like the American Academy of Neurology, the American Academy of Allergy, Asthma & Immunology, or published NIH-funded research carry significant weight.

For off-label indications, the evidence section becomes even more critical. The letter should reference controlled trials, systematic reviews, or consensus guidelines from recognized medical organizations.

Consequences of Not Treating with IVIG

What happens if this patient does not receive IVIG? The letter should paint a clear, evidence-based picture of the expected disease course without treatment: progressive disability, hospitalization risk, loss of independence, potential organ damage, or other measurable consequences. This section should be specific to the patient, not generic.

Treatment Plan

The letter should specify the requested IVIG product (or state that any FDA-approved product is acceptable), the dose based on body weight, the infusion frequency, and the expected duration of therapy. It should also describe how treatment response will be monitored and what criteria would be used to assess ongoing medical necessity.

Mistakes That Weaken a Medical Necessity Letter

Even well-intentioned letters can fail because of avoidable errors:

• Being too brief. A one-paragraph letter that says “patient needs IVIG for CIDP” gives the reviewer nothing to approve. Insurance medical directors have told physician groups that the most common reason for denial is insufficient clinical information, not lack of medical necessity.
• Missing the insurer’s specific criteria. Each insurer has its own medical policy for IVIG. If the letter does not address the specific criteria in that policy, the reviewer may deny based on “criteria not met” even when the patient clearly qualifies. Ask the insurer for its clinical policy before the letter is written.
• Using subjective language instead of data. “Patient is doing poorly” is subjective. “Patient’s ONLS score has worsened from 3 to 7, and she now requires a wheelchair for distances over 50 feet” is objective and compelling.
• Omitting treatment history. Failing to document previously tried and failed therapies almost guarantees a step therapy denial.

The Peer-to-Peer Review Process

When a medical necessity letter and supporting documentation are not enough to secure approval, the next step is often a peer-to-peer review, a direct phone conversation between the prescribing physician and the insurance company’s medical director.

Peer-to-peer reviews can be remarkably effective. They give the treating doctor the opportunity to provide context that does not translate well to paper: the nuances of the patient’s presentation, the clinical reasoning behind the treatment choice, and the urgency of the situation.

How Peer-to-Peer Reviews Work

1. The prescribing physician requests the review, usually through the insurer’s provider services line
2. A call is scheduled, typically within 5 to 10 business days, though urgent cases can be expedited
3. The physician speaks directly with the insurer’s medical director or reviewing physician
4. The medical director may overturn the denial on the call or within a few business days afterward

Preparing Your Doctor for the Call

Physicians are busy. A peer-to-peer call that goes well is one where the doctor is prepared. You can help by:

• Providing a written summary of your key symptoms, functional limitations, and treatment timeline
• Noting which specific criteria the insurer cited in the denial letter
• Sharing any recent test results or clinical changes that support the need for IVIG
• Asking your doctor’s office if they have confirmed the call time and who the insurer’s reviewer will be

The medical necessity letter is not just paperwork. It is the clinical argument for your treatment, and the peer-to-peer review is its oral defense. Together, they are the most powerful tools available for overcoming an insurance denial for IVIG therapy.

Be involved. Ask questions. Provide your doctor with the information they need to write the strongest possible case. Your participation in this process matters more than most patients realize.